Top

Published in:

01-01-2021 | Glioblastoma | Editorial

The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system

Author: Takashi Komori

Published in: Brain Tumor Pathology | Issue 1/2021

Excerpt

While the classifications of adult diffuse gliomas according to the WHO classification of tumors of the central nervous system (CNS) were considerably updated in the 2016 revision (WHO2016CNS) based on the isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion [6, 10], the classification of diffuse gliomas in children and adolescents has not been updated due to a lack of sufficient evidence to do so. The WHO2016CNS instead only gave these lesions tentative nomenclature, such as “pediatric diffuse astrocytoma” and “pediatric-type oligodendroglioma” as a boxed article [10]. …

Collins VP, Jones DTW, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:775–788CrossRef

Ellison DW, Hawkins C, Jones DTW et al (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 137:683–687CrossRef

Jain SU, Khazaei S, Marchione DM et al (2020) Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proc Natl Acad Sci USA 117:27354–27364CrossRef

Jones DTW, Bandopadhayay P, Jabado N (2019) The power of human cancer genetics as revealed by low-grade gliomas. Annu Rev Genet 53:483–503CrossRef

Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447CrossRef

Komori T (2020) Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification. Brain Tumor Pathol 37:1–4CrossRef

Komori T, Arai N (2013) Dysembryoplastic neuroepithelial tumor, a pure glial tumor? Immunohistochemical and morphometric studies. Neuropathology 33:459–468CrossRef

Krishnatry R, Zhukova N, Guerreiro Stucklin AS et al (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122:1261–1269CrossRef

Kurozumi K, Nakano Y, Ishida J et al (2019) High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene. Brain Tumor Pathol 36:121–128CrossRef

10.

Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system. International Agency for Research On Cancer, Lyon

11.

Louis DN, Wesseling P, Aldape K et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principal recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. https://doi.org/10.1111/bpa.12832CrossRefPubMed

12.

Northcott PA, Pfister SM, Jones DT (2015) Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncol 16:e293-302CrossRef

13.

Pujadas E, Chen L, Rodriguez FJ (2019) Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors. Brain Tumor Pathol 36:40–51CrossRef

14.

Reuss DE, Mamatjan Y, Schrimpf D et al (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867–873CrossRef

15.

Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8:30CrossRef

16.

Tateishi K, Nakamura T, Yamamoto T (2019) Molecular genetics and therapeutic targets of pediatric low-grade gliomas. Brain Tumor Pathol 36:74–83CrossRef

17.

Thom M, Blumcke I, Aronica E (2012) Long-term epilepsy-associated tumors. Brain Pathol 22:350–379CrossRef

18.

Wisoff JH, Sanford RA, Heier LA et al (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68:1548–1554 (discussion 1554–1545)CrossRef

19.

Yoshimoto K, Hatae R, Sangatsuda Y et al (2017) Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34:103–112CrossRef

20.

Zhang J, Wu G, Miller CP et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612CrossRef

Title: The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system
Author: Takashi Komori
Publication date: 01-01-2021
Publisher: Springer Singapore
Keywords: Glioblastoma
Astrocytoma
Glioma
Glioma
Astrocytoma
Glioblastoma
Astrocytoma
Glioblastoma
Oligodendroglioma
Glioma
Published in: Brain Tumor Pathology / Issue 1/2021
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-020-00392-w

At a glance: The STEP trials

Springer Medicine

The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Methylation profiling-based diagnosis of radiologically suspected congenital glioma

Genetic characterization of an aggressive optic nerve pilocytic glioma

Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features

Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas

EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations

H3 G34-mutant high-grade glioma